Results 81 to 90 of about 8,359 (180)
Pharmacology Research & PerspectivesObesity, a global health challenge, necessitates innovative approaches for effective management. Targeting gut peptides in the development of anti‐obesity pharmaceuticals has already demonstrated significant efficacy.
Igor Rubinić +2 more
doaj +1 more source
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
Drug Design, Development and Therapy, 2008 Gina Ryan, Tim A Briscoe, Lynette JobeCollege of Pharmacy and Health Sciences, Mercer University, Atlanta, Georgia, USAAbstract: Pramlintide (Symlin®), a synthetic analog of a neurohormone amylin, was approved by the US Food and Drug ...
Tim A Briscoe, Lynette Jobe +1 more
doaj
Scientific ReportsType 2 diabetes mellitus and Alzheimer’s disease, are two closely related pathological situations that are connected at the molecular level. In recent years, amylin, which is co-secreted with insulin, has been proposed for being a main actor in this ...
Carlos González-Blanco +8 more
doaj +1 more source
Amylin as a Neuroendocrine Hormone
The Scientific World Journal, 2001 Andrew A. Young
doaj +1 more source
Brain Amylin Signaling, Feeding, and Reward. [PDF]
Compr PhysiolMietlicki-Baase EG.
europepmc +1 more source
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. [PDF]
Endocrinol Diabetes MetabKamrul-Hasan ABM +5 more
europepmc +1 more source
Peripheral amylin modulation rebalances brain glycolysis and Tau-Ser214 phosphorylation via cAMP-PKA signaling. [PDF]
iScienceDavargaon RS +14 more
europepmc +1 more source
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. [PDF]
Metabol OpenLempesis IG, Dalamaga M.
europepmc +1 more source
Hypothalamus-liver talks: whispers in the language of metabolism. [PDF]
Rev Endocr Metab DisordFerreira V +5 more
europepmc +1 more source